Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, ...

ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

Two anti-transferrin receptor (TfR) nanobodies, V H H123 specific for mouse TfR and V H H188 specific for human TfR (huTfR) were used to track transplants non-invasively by PET/CT in mouse models, ...

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches ...

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.